Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Smolen

Showing results (11-20 of 863) with videos related to

Pageof 87
Sort By:
Annals of the Rheumatic Diseases|February 5, 2022
Response to: Where are the women 'Heroes and Pillars of Rheumatology'?Josef S Smolen
Annals of the Rheumatic Diseases|May 25, 2026
Greetings from the editor - 2026/2Josef S Smolen
Rheumatic Diseases Clinics of North America|October 1, 2019
Treat to Target in Rheumatology: A Historical Account on Occasion of the 10th AnniversaryJosef S Smolen
Scandinavian Journal of Rheumatology. Supplement|February 11, 2000
Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritisJ S Smolen
Annals of the Rheumatic Diseases|March 4, 2021
Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by CharlesJosef S Smolen
Annals of the Rheumatic Diseases|May 18, 2005
In the middle of the decadeJ S Smolen
Arthritis Research & Therapy|August 11, 2006
Expanding the frontiers of therapyJosef S Smolen
The Journal of Rheumatology. Supplement|July 6, 2007
What is the place of recently approved T cell-targeted and B cell-targeted therapies in the treatment of rheumatoid arthritis? Lessons from global clinical trialsJosef S Smolen
Annals of the Rheumatic Diseases|December 26, 2025
Greetings from the editor-2026Josef S Smolen
Clinical and Experimental Rheumatology|October 18, 2012
Treat-to-target: rationale and strategiesJosef S Smolen
Pageof 87

Showing results (11-20 of 863) with videos related to

Sort By:
Pageof 87
Annals of the Rheumatic Diseases|February 5, 2022
Response to: Where are the women 'Heroes and Pillars of Rheumatology'?Josef S Smolen
Annals of the Rheumatic Diseases|May 25, 2026
Greetings from the editor - 2026/2Josef S Smolen
Rheumatic Diseases Clinics of North America|October 1, 2019
Treat to Target in Rheumatology: A Historical Account on Occasion of the 10th AnniversaryJosef S Smolen
Scandinavian Journal of Rheumatology. Supplement|February 11, 2000
Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritisJ S Smolen
Annals of the Rheumatic Diseases|March 4, 2021
Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by CharlesJosef S Smolen
Annals of the Rheumatic Diseases|May 18, 2005
In the middle of the decadeJ S Smolen
Arthritis Research & Therapy|August 11, 2006
Expanding the frontiers of therapyJosef S Smolen
The Journal of Rheumatology. Supplement|July 6, 2007
What is the place of recently approved T cell-targeted and B cell-targeted therapies in the treatment of rheumatoid arthritis? Lessons from global clinical trialsJosef S Smolen
Annals of the Rheumatic Diseases|December 26, 2025
Greetings from the editor-2026Josef S Smolen
Clinical and Experimental Rheumatology|October 18, 2012
Treat-to-target: rationale and strategiesJosef S Smolen
Pageof 87